Administration with Vaccinia Virus Encoding Canine Parvovirus 2 vp2 Elicits Systemic Immune Responses in Mice and Dogs
Administration with Vaccinia Virus Encoding Canine Parvovirus 2 vp2 Elicits Systemic Immune Responses in Mice and Dogs
复制标题
给予编码犬细小病毒 2 vp2 的痘苗病毒可引发小鼠和狗的全身免疫反应
DOI：
10.1089/vim.2019.0164
复制
发表时间：
2020-05-04
期刊：
影响因子：
2.2
通讯作者：
Li, Yaoming
中科院分区：
文献类型：
--
作者：
Zhao, Wanbo;Wang, Xiaomei;Li, Yaoming
2 型犬细小病毒 (CPV2) 是一种高度传染性的病毒，可导致幼犬患上严重且常常致命的疾病。尽管减毒疫苗已广泛使用，但更安全、更稳定和更有效的 CPV2 候选疫苗仍在探索中。牛痘病毒（VV）已被证明是一种安全、稳定、有效的疫苗载体。在这项研究中，我们生成了一种基于 VV 的 CPV2 候选疫苗 (VV-CPV-VP2)，然后评估了其在小鼠和狗中的免疫原性。 CPV2的外源vp2基因取代了VV的主要毒力基因血凝素(ha)，在体外高效稳定表达。随后，小鼠肌内免疫诱导了强大而持久的全身免疫反应，包括针对 CPV2a 和 CPV2b 的中和抗体，以及 CPV2-VP2 特异性干扰素 γ (IFN-gamma) 分泌 T 细胞。此外，给予高剂量的VV-CPV-VP2不会对小鼠造成明显的副作用，因此表明该候选疫苗具有显着的安全性。最重要的是，单剂 VV-CPV2-VP2 疫苗接种可引发大量抗体反应，并为接种减毒 CPV2 疫苗的狗提供类似的保护。总的来说，这项研究表明 VV-CPV2-VP2 可用作预防犬 CPV2 感染的有前途的候选疫苗。
Canine parvovirus type 2 (CPV2) is a highly contagious cause of serious and often fatal disease in young dogs. Despite the widespread availability of attenuated vaccines, safer, more stable, and more effective CPV2 vaccine candidates are still under exploration. Vaccinia virus (VV) has already been proved to be a safe, stable, and effective vaccine vector. In this study, we generated a VV-based CPV2 vaccine candidate (VV-CPV-VP2) and then evaluated its immunogenicity in mice and dogs. The exogenous vp2 gene of CPV2, which replaced the major virulence gene hemagglutinin (ha) of VV, expressed efficiently and stably in vitro. Subsequently, intramuscular immunization of mice induced robust and lasting systemic immune responses, including neutralizing antibody against both CPV2a and CPV2b, and CPV2-VP2-specific interferon gamma (IFN-gamma) secreting T cell. In addition, administration with a high-dose of VV-CPV-VP2 did not cause significant side effects for mice, thus indicating marked safety of this vaccine candidate. Most importantly, a single-dose vaccination of VV-CPV2-VP2 elicited substantial antibody responses and provided comparable protection for dogs with attenuated CPV2 vaccine. Collectively, this study demonstrated that VV-CPV2-VP2 could be used as a promising vaccine candidate preventing CPV2 from infection for dogs.